Association Between Health Insurance Type and Adverse Outcomes for Children and Young Adults With Type 1 Diabetes and Coronavirus Disease 2019.
Journal
Diabetes spectrum : a publication of the American Diabetes Association
ISSN: 1040-9165
Titre abrégé: Diabetes Spectr
Pays: United States
ID NLM: 8913432
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
29
11
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
ppublish
Résumé
Health insurance coverage type differs significantly by socioeconomic status and racial group in the United States. The aim of this study was to determine whether publicly insured children and young adults with type 1 diabetes were more likely to experience adverse outcomes compared with privately insured patients with acute coronavirus disease 2019 (COVID-19) infections. Data from 619 patients with previously established type 1 diabetes who were <24 years of age with acute COVID-19 infections were analyzed from the T1D Exchange COVID-19 surveillance registry. Data for the registry was collected from 52 endocrinology clinics across the United States using an online survey tool. Each site completed the survey using electronic health record data between April 2020 and December 2021. Of the 619 patients included in this study, 257 had public insurance and 362 had private insurance. Of the 257 publicly insured patients with COVID-19, 57 reported severe adverse outcomes (22%), defined as diabetic ketoacidosis (DKA) or severe hypoglycemia. In comparison, there were 25 reported adverse outcomes (7%) among the 362 privately insured patients. Our data reveal high rates of hospitalization and DKA among publicly insured racial/ethnic minority children and young adults with type 1 diabetes and COVID-19.
Sections du résumé
Background
UNASSIGNED
Health insurance coverage type differs significantly by socioeconomic status and racial group in the United States. The aim of this study was to determine whether publicly insured children and young adults with type 1 diabetes were more likely to experience adverse outcomes compared with privately insured patients with acute coronavirus disease 2019 (COVID-19) infections.
Methods
UNASSIGNED
Data from 619 patients with previously established type 1 diabetes who were <24 years of age with acute COVID-19 infections were analyzed from the T1D Exchange COVID-19 surveillance registry. Data for the registry was collected from 52 endocrinology clinics across the United States using an online survey tool. Each site completed the survey using electronic health record data between April 2020 and December 2021.
Results
UNASSIGNED
Of the 619 patients included in this study, 257 had public insurance and 362 had private insurance. Of the 257 publicly insured patients with COVID-19, 57 reported severe adverse outcomes (22%), defined as diabetic ketoacidosis (DKA) or severe hypoglycemia. In comparison, there were 25 reported adverse outcomes (7%) among the 362 privately insured patients.
Conclusion
UNASSIGNED
Our data reveal high rates of hospitalization and DKA among publicly insured racial/ethnic minority children and young adults with type 1 diabetes and COVID-19.
Identifiants
pubmed: 38024220
doi: 10.2337/ds23-0002
pii: DS230002
pmc: PMC10654127
doi:
Banques de données
figshare
['10.2337/figshare.24079248']
Types de publication
Journal Article
Langues
eng
Pagination
398-402Informations de copyright
© 2023 by the American Diabetes Association.
Déclaration de conflit d'intérêts
O.E. is the principal investigator for research projects funded through his institution by Dexcom, Eli Lilly, and Medtronic; he is also a member of the Medtronic Diabetes Health Inequity Advisory Board. No other potential conflicts of interest relevant to this article were reported.
Références
Clin Diabetes. 2020 Apr;38(2):141-151
pubmed: 32327886
Pediatr Diabetes. 2022 Dec;23(8):1322-1340
pubmed: 36537534
J Diabetes Sci Technol. 2022 Jul;16(4):825-833
pubmed: 34632819
Pediatrics. 2006 Aug;118(2):577-85
pubmed: 16882810
PLoS One. 2022 Apr 19;17(4):e0266809
pubmed: 35439266
J Diabetes. 2021 Aug;13(8):681-687
pubmed: 33855813
J Hosp Med. 2021 Aug 18;:
pubmed: 34424192
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1755-e1762
pubmed: 33410917
Pediatr Diabetes. 2005 Jun;6(2):79-83
pubmed: 15963034
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Pediatr Endocrinol Diabetes Metab. 2020;26(4):167-175
pubmed: 33554490
J Clin Endocrinol Metab. 2022 Jun 16;107(7):1948-1955
pubmed: 35380700
Diabet Med. 2021 Jan;38(1):e14417
pubmed: 33020999
MMWR Morb Mortal Wkly Rep. 2020 May 08;69(18):545-550
pubmed: 32379729
Pediatr Diabetes. 2022 Nov;23(7):835-856
pubmed: 36250645
Diabetes Care. 2021 Aug;44(8):e160-e162
pubmed: 34385347
Am J Physiol Endocrinol Metab. 2022 Jan 1;322(1):E44-E53
pubmed: 34779657
MMWR Morb Mortal Wkly Rep. 2020 Jun 19;69(24):759-765
pubmed: 32555134
JAMA. 2003 Sep 17;290(11):1486-93
pubmed: 13129989